iv of pancuronium was administered initially and a second bolus of 0.05 mg·kg -1 15 min later if the TOF response at the orbicularis oculi muscle was not completely abolished, using a standard peripheral nerve stimulator with surface electrodes. The initial dose of pancuronium was found to completely abolish the TOF response in only 36% of patients, whereas 68% of patients had a completely abolished response following administration of the second dose (Table) . Therefore, a "standard intubating dose" of pancuronium (as determined in healthy anesthetized patients and expected to achieve complete paralysis) has only limited relevance in critical care patients. Our results strongly suggest that bolus injections of NMBD in ICU patients should be titrated to the specific target required for brief relaxation, and that TOF monitoring should be used systematically, as recommended for long-term infusions of NMBD. 
